Literature DB >> 11149484

Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism.

J R Zanchetta1, C E Bogado.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11149484     DOI: 10.1359/jbmr.2001.16.1.189

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


× No keyword cloud information.
  11 in total

Review 1.  Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects.

Authors:  Leonidas H Duntas; Nikolaos Stathatos
Journal:  Endocrine       Date:  2011-03-26       Impact factor: 3.633

Review 2.  Hyperparathyroidism in the elderly patient.

Authors:  Rebecca Sims; Charanjeit Ubhi; David Hosking
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 3.  Current pharmacological options for the management of primary hyperparathyroidism.

Authors:  Peter Vestergaard
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 4.  Bone turnover markers in primary hyperparathyroidism.

Authors:  Aline G Costa; John P Bilezikian
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

Review 5.  Therapy for patients with CKD and low bone mineral density.

Authors:  Susan M Ott
Journal:  Nat Rev Nephrol       Date:  2013-10-08       Impact factor: 28.314

6.  Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism.

Authors:  Claudio Marcocci; Philippe Chanson; Dolores Shoback; John Bilezikian; Laureano Fernandez-Cruz; Jacques Orgiazzi; Christoph Henzen; Sunfa Cheng; Lulu Ren Sterling; John Lu; Munro Peacock
Journal:  J Clin Endocrinol Metab       Date:  2009-05-26       Impact factor: 5.958

7.  Comparison of alendronate and raloxifene for the management of primary hyperparathyroidism.

Authors:  G Akbaba; S Isik; Y Ates Tutuncu; U Ozuguz; D Berker; S Guler
Journal:  J Endocrinol Invest       Date:  2013-09-27       Impact factor: 4.256

Review 8.  Persistent and recurrent hyperparathyroidism.

Authors:  Nadine R Caron; Cord Sturgeon; Orlo H Clark
Journal:  Curr Treat Options Oncol       Date:  2004-08

Review 9.  Strategies to improve physical activity by exercise training in patients with chronic kidney disease.

Authors:  Yoshiyuki Morishita; Daisuke Nagata
Journal:  Int J Nephrol Renovasc Dis       Date:  2015-03-10

10.  Raloxifene improves skeletal properties in an animal model of cystic chronic kidney disease.

Authors:  Christopher L Newman; Amy Creecy; Mathilde Granke; Jeffry S Nyman; Nannan Tian; Max A Hammond; Joseph M Wallace; Drew M Brown; Neal Chen; Sharon M Moe; Matthew R Allen
Journal:  Kidney Int       Date:  2016-01-04       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.